Request Demo
Last update 01 Nov 2025
Recombinant humanized anti-PD-1 monoclonal antibody(Anhui Anke Biotechnology (Group) Co., Ltd.)
Last update 01 Nov 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with Recombinant humanized anti-PD-1 monoclonal antibody(Anhui Anke Biotechnology (Group) Co., Ltd.)CTR20191892
重组抗PD1人源化单克隆抗体注射液对晚期恶性肿瘤患者的安全性、耐受性、药代动力学及初步疗效的I/II期临床研究
[Translation] Phase I/II clinical study on the safety, tolerability, pharmacokinetics and preliminary efficacy of recombinant anti-PD1 humanized monoclonal antibody injection in patients with advanced malignant tumors
100 Clinical Results associated with Recombinant humanized anti-PD-1 monoclonal antibody(Anhui Anke Biotechnology (Group) Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Recombinant humanized anti-PD-1 monoclonal antibody(Anhui Anke Biotechnology (Group) Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Recombinant humanized anti-PD-1 monoclonal antibody(Anhui Anke Biotechnology (Group) Co., Ltd.)
Login to view more data
100 Deals associated with Recombinant humanized anti-PD-1 monoclonal antibody(Anhui Anke Biotechnology (Group) Co., Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 2 | China | 30 Jul 2019 | |
| Esophageal Carcinoma | IND Application | China | 17 Jan 2019 | |
| Lung Cancer | IND Application | China | 17 Jan 2019 | |
| Lymphoma | IND Application | China | 17 Jan 2019 | |
| Transitional Cell Carcinoma | IND Application | China | 17 Jan 2019 | |
| Triple Negative Breast Cancer | IND Application | China | 17 Jan 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free